Notícias

RapAdmin

HQNyAzFbcAAkxhZ
HQNyAzFbcAAkxhZ1536×1024 284 KB

Researchers at Xuanwu Hospital, Capital Medical University screened 118 environmental, lifestyle, early-life, psychosocial and socioeconomic exposures against biological-age acceleration in 236,099 UK Biobank participants, then repeated the analysis separately in men and women. Lifestyle dominated every other domain by a wide margin. Women showed a slightly stronger response to the same adverse lifestyle exposures than men, but men carried a far larger preventable burden at the population level simply because more of them live badly (73% of men versus 56% of women in the intermediate or unfavourable lifestyle tertiles). Roughly a quarter of accelerated-aging cases in the whole cohort were attributable to the five modifiable domains combined. Reproductive variables including menopause, early menarche and stillbirth added independent, though modest, risk in women.

Aging is not a single process running at a single speed. Two people born the same year can be biologically a decade apart, and researchers now routinely quantify that gap using blood-based “clocks” that estimate biological age from ordinary lab values. The question this paper asks is deceptively simple: what actually drives the gap, and does it work the same way in men and women?

The team ran what is essentially a hypothesis-free sweep. Rather than picking a favourite exposure and testing it, they threw 118 candidate factors at the data at once, an approach borrowed from genomics called an exposure-wide association study. Everything went in: air pollution, greenspace, mobile-phone use, television hours, sleep, supplements, salt at the table, sunscreen habits, loneliness, income, employment, childhood adversity, and for women, menstrual and reproductive history.

The result is a clean hierarchy. Lifestyle beat everything. People in the worst lifestyle tertile had roughly two and a half times the odds of being classified as biologically accelerated compared with the best tertile. Socioeconomic status came second, psychosocial factors third, early-life factors fourth. Environmental exposures, the domain that gets the loudest press coverage, contributed almost nothing once everything else was accounted for.

The big idea, though, is the sex split. Women appeared more sensitive to the same bad habits: the odds ratio for an unfavourable lifestyle was 2.88 in women versus 2.37 in men, even though similar proportions were exposed. But when the authors asked a different question, how much accelerated aging could be erased if everyone moved to a favourable profile, the answer flipped. Men had 41.7% of cases theoretically preventable; women only 15.0%. The reason is not biology but arithmetic: more men are exposed in the first place.

There is a caveat the paper handles too gently. The two clocks contradict each other. On one measure women look 17 years older than men on average; on the other, men look slightly older. Since both measures were calculated by comparing everyone against the pooled average of the whole cohort, one sex is forced above the line and the other below it by construction. What the data show robustly is that lifestyle matters enormously and that men have more room to improve. What they do not show, yet, is that women’s biology ages faster.

Actionable Insights

The practical content here is unglamorous and consistent. Effect sizes below are standardised so they can be compared with each other. Cohen’s d of 0.2 is small, 0.5 moderate, 0.8 large.

Diet was the single strongest protective factor found. The best diet score versus the worst carried d = 0.76 in women and d = 0.60 in men, translating to a biological age roughly 3.0 years younger on the phenotypic clock and 7.7 years younger on the physiological clock. That is the largest modifiable signal in the entire 118-factor screen.

Television time was the strongest behavioural risk factor in women: three or more hours daily was associated with d = 0.42, about 1.7 years of added phenotypic age.

Habitually adding salt at the table carried d = 0.32 overall and d = 0.38 in men, an unusually large effect for such a small habit.

Routine sun and UV protection was protective at d = 0.25.

Overall, moving from the worst to the best lifestyle profile corresponds to d = 0.51, which in plain terms is roughly a 15 percentage-point absolute drop in the chance of being classified as an accelerated ager.

Caution: this is cross-sectional observational data. These are associations, not demonstrated causes.

Context and Source

  • Open Access Paper: Sex differences in aging acceleration: higher susceptibility in women, greater preventability in men
  • Authors: Ziye Ren, Shuiyue Quan, Fangyu Li, Longfei Jia
  • Institution: Department of Neurology and Innovation Center for Neurological Disorders, Xuanwu Hospital, Capital Medical University; National Clinical Research Center for Geriatric Diseases, Beijing, China
  • Country: China (data source: UK Biobank, United Kingdom)
  • Journal: npj Aging (Nature Portfolio, published in partnership with the Japanese Society of Anti-Aging Medicine), published online 20 August 2026.
  • Funding: Brain Science and Brain-like Intelligence Technology National Science and Technology Major Project, National Natural Science Foundation of China, Beijing Hospitals Authority, Xuanwu Hospital. No competing interests declared.
    Journal impact: The impact score of this journal is 13.0 (2025 Journal Impact Factor; 5-year JIF 12.2), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

RapAdmin

HeatRisks
HeatRisks2752×1536 452 KB

A Stanford, Penn State, Purdue and Nebraska team combined laboratory-derived human heat tolerance limits for three adult age bands with 14 climate models and gridded, age-stratified population projections to ask a question nobody had properly asked: what happens to global heat risk estimates when you stop assuming everyone thermoregulates like a 25-year-old? The answer is that the risk picture gets dramatically worse. Older adults face more frequent and more geographically widespread uncompensable heat stress at 1.5 degrees C of warming than young adults do at 4 degrees C. Using age-appropriate thresholds instead of young-adult thresholds multiplies the estimated globally exposed population by a factor of 8.2 at 1.5 degrees C. Under 3 degrees C, roughly 2 billion people, including 1.3 billion adults over 60, would experience at least 180 hours per year of conditions in which the human body cannot shed heat fast enough to hold core temperature steady.

There is a temperature and humidity combination beyond which the human body simply loses. Sweat cannot evaporate fast enough, blood cannot be pushed to the skin fast enough, and core temperature starts climbing and does not stop. Physiologists call this the point of uncompensable heat stress. For a fit young adult in a climate chamber, that point sits near a wet-bulb temperature of about 30.6 degrees C in humid conditions, well below the 35 degrees C figure that dominated climate reporting for a decade.

The new work in The Lancet Planetary Health does something more uncomfortable. It takes the fact that thermoregulation is an aging phenotype and puts a number on it at planetary scale.

Sweat gland output falls with age. The skin’s ability to dilate its blood vessels falls with age. Maximum cardiac output and chronotropic reserve fall with age. The result is that an older adult reaches the uncompensable point in conditions a young adult tolerates comfortably. Previous global projections ignored this entirely, applying young-adult limits to grandparents.

Correcting that assumption changes everything. The headline finding is a direct trade-off between biology and physics: the physiological penalty of being over 60 is worth roughly 2.5 degrees C of global warming. Older adults living in a 1.5 degrees C world are in more thermal trouble than young adults living in a 4 degrees C world. Aging is, on this metric, a more powerful risk multiplier than the entire remaining span of plausible twenty-first century warming.

The geography is brutally specific. The Indo-Gangetic Plain, the Persian Gulf coast, eastern China, west Africa and southeast Asia dominate. In Delhi, Lahore and Dubai, older adults would accumulate close to or more than 1000 hours per year of uncompensable heat even at 1.5 degrees C. Push past 3 degrees C and those cities deliver sustained day and night exposure for three consecutive months, coinciding with the Kharif cropping season that feeds more than half a billion people. Bangkok reaches 3840 hours per year at 4 degrees C, which is 44 percent of the calendar.

Thirteen countries combine poverty rates above 50 percent with mass older-adult exposure. India, Pakistan, Bangladesh, Myanmar and Niger appear on every list. Each additional degree of warming adds roughly one billion people to the exposed population.

Actionable Insights

What the paper demonstrates is an exposure gradient, not a treatment effect. The meaningful magnitudes are ratios. Being over 60 rather than under 40 raises your probability of experiencing at least 180 hours per year of uncompensable heat by roughly 13-fold at 1.5 degrees C of warming, using this paper’s own numbers. Put differently, over-60s make up about a fifth of the adult population but 78.5 percent of everyone exposed at 1.5 degrees C, a 3.7-fold over-representation. Going from 1 to 4 degrees C of warming takes global exposure from 2.3 percent to 35.6 percent of adults, a 15.5-fold relative increase and a 33 percentage point absolute increase.

What follows practically. First, thermoregulatory capacity is a modifiable aging biomarker, and the authors cite evidence that lifelong regular physical activity attenuates its decline. Aerobic fitness and heat acclimation training measurably raise sweat rate and plasma volume. Second, most heat deaths in older adults happen indoors, so reliable cooling is a longevity intervention, not a comfort purchase. Third, if you are over 60 and take beta blockers, diuretics or anticholinergics, your personal threshold is lower than the one modelled here. Fourth, location is a longevity variable with a quantifiable slope.

Context and Source

  • Open Access Paper: Exceeding human heat tolerance in a warming, ageing world: a global projection modelling study.
  • Institutions: Stanford University School of Medicine and Woods Institute for the Environment (lead); University of Nebraska Omaha; Pennsylvania State University Noll Laboratory, Department of Kinesiology; Purdue University; Texas Health Presbyterian Hospital Dallas; UT Southwestern Medical Center; University of Georgia.
  • Country: United States.
  • Journal: The Lancet Planetary Health, 2026.
  • Funding: US NIH, NSF, NASA, Yale Institute for Biospheric Studies, The Rockefeller Foundation.
  • Impact evaluation: The journal reported a Journal Impact Factor of 24.1 and a CiteScore of 28.4 in its most recent self-reported metrics, with more recent third-party estimates in the 20 to 21 range as the journal’s citation base matures. The impact score of this journal is approximately 20 to 24, evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a High impact journal.

Leitura Relacionada:

RapAdmin

Elastin
Elastin2752×1536 385 KB

Elastin is the rubber-band protein that lets your aorta recoil with every heartbeat, your lungs spring back with every breath, and your skin snap back when pinched. You make almost all of it before you finish growing, and you never meaningfully replace it. Over decades of mechanical fatigue, sunlight, and enzyme attack, it shatters into short peptides that leak into the bloodstream. This review argues that those fragments are not passive debris but active hormone-like signals that switch on immune cells and drive chronic, body-wide inflammation. The author, a dermatology researcher at the University of Michigan, sets out to answer a specific question: which organs are actually producing this circulating debris? His answer is that three tissues dominate, the aorta, the lungs, and the sun-damaged dermis, each with its own signature set of protein-cutting enzymes. The practical payoff he proposes is source-resolved biomarkers, meaning a future blood test that could tell a clinician whether a given patient’s inflammation is coming mainly from their arteries, their lungs, or their skin, and therefore which tissue to treat.

There is a protein in your body that is almost as old as you are. Elastin, the elastic fibre that gives arteries their recoil and lungs their spring, is laid down in the womb and in early childhood and then, for practical purposes, never renewed. By the time you are fifty, the elastin in your aorta is fifty years old and has been stretched roughly two billion times.

That longevity is the problem. A new mini-review from Taihao Quan at the University of Michigan pulls together an emerging and genuinely provocative idea: as elastin finally fatigues and fractures, the pieces it sheds are not inert rubbish. They are signalling molecules. One short sequence in particular, a six-amino-acid motif written VGVAPG, docks onto a receptor complex on the surface of monocytes and macrophages and tells them to start producing inflammatory cytokines. The result is inflammaging, the smouldering low-grade inflammation that tracks almost every disease of later life.

The evidence that pushed this from curiosity to serious hypothesis came in 2025, when a team led by Yi and colleagues injected these fragments into young mice at concentrations matching those found in elderly humans. The young animals put on fat, developed fatty livers, lost muscle, performed worse on treadmills, and died sooner. Blocking the receptor’s key enzyme, an enzyme called NEU1, did the reverse: median lifespan rose by around 17 per cent in males.

Quan’s contribution is to ask a question that sounds pedantic but is not. If these fragments matter, where are they coming from? Elastin, unlike collagen, is not everywhere. It is concentrated in exactly three places that take a beating: the aorta and large arteries, where it makes up 30 to 50 per cent of the vessel wall’s dry weight; the lung, whose alveoli inflate and deflate about 15,000 times a day in a bath of inhaled oxidants; and the dermis, which absorbs a lifetime of ultraviolet radiation. Each of these tissues degrades its elastin using a slightly different mix of enzymes.

The implication is a shift in how we might think about anti-inflammatory medicine. Rather than blanket immunosuppression, you could read the precise chemical signature of a patient’s circulating fragments, identify which organ is the dominant source, and intervene there. Someone whose fragments carry the fingerprint of macrophage elastase is telling you about their lungs. Someone whose fragments look neutrophil-cut may be telling you about sun-damaged skin.

That test does not exist yet. Neither does a usable drug. But the framing is new, and it is testable.

Actionable Insights

Be clear about what this review can and cannot do for you. It is a hypothesis paper with no human intervention data, so there is no supplement, dose, or protocol to take away from it. What it offers is a mechanistic reason to take three unglamorous behaviours more seriously, plus one number.

The number is this: in mice, blocking the receptor enzyme NEU1 with a compound called DANA raised median lifespan by 17.4 per cent in males and 12.2 per cent in females. Reconstructing the strength of that result from the reported statistics, a treated mouse was roughly a third as likely to die at any given moment as an untreated one. That is a large effect by animal-study standards, large enough that it should be treated with suspicion until someone repeats it. DANA is not a drug you can obtain, and nothing equivalent has been tested in a person.

The behaviours the mechanism supports are sun protection, not smoking, and blood pressure control. Each reduces the mechanical or chemical load on one of the three elastin reservoirs. None has a measured effect on circulating elastin fragments in humans.

Context and Source

  • Paywalled Paper: Circulating elastin fragments drive systemic aging: Where do pro-aging elastin fragments come from? A mini-review
  • Author: Taihao Quan, sole author
  • Institution: Department of Dermatology, University of Michigan Medical School, Ann Arbor, Michigan
  • Country: United States
  • Journal: Mechanisms of Ageing and Development, volume 233 (2026), article 112218, published by Elsevier
  • Impact evaluation: The impact score of this journal is 6.5 (Journal Impact Factor, Web of Science, most recent release), evaluated against a typical high-end range of 0 to 60+ for top general science, therefore this is a Medium impact journal.

Leitura Relacionada:

RapAdmin

CatStudy
CatStudy1920×1072 316 KB

A small randomized, double-blind, placebo-controlled trial reports that PURR-001, a once-weekly oral capsule combining a low-dose rapamycin analog, mirtazapine, and acarbose, produced a larger gain in body mass and back-muscle thickness than placebo in elderly sarcopenic cats over 12 weeks. Treated cats gained about 7.4 percent body mass versus 1.1 percent on placebo, and their epaxial (spinal) muscle height rose about 22.8 percent versus 9.0 percent. Blood safety markers stayed stable.

Muscle wasting in old age is one of the most reliable signatures of biological aging, and it is not unique to humans. Cats lose muscle too, and until now no drug had been formally tested against the age-related version of that decline, known as sarcopenia. A team backed by a Delaware-registered startup called The Cat Health Company, working with veterinary clinics in Romania and chemists at Politehnica Bucharest, set out to change that with a candidate they call PURR-001.

The big idea is deliberately unglamorous. Rather than betting on a single miracle molecule, the researchers built a combination pill that pokes at three connected levers of mammalian aging at once: nutrient sensing, low-grade chronic activation of the growth pathway mTOR, and subclinical insulin resistance. The active ingredients are a low dose of a rapamycin-like mTOR inhibitor, the appetite stimulant mirtazapine, and the blood-sugar drug acarbose. Two of these, rapamycin and acarbose, are the same pairing that has produced some of the largest lifespan extensions on record in the US National Institute on Aging’s mouse testing program, which is almost certainly why they appear here together.

Thirty-five elderly cats were randomly assigned to the drug or a matching placebo, and neither owners nor assessing vets knew which was which. Twelve weeks later, the cats on PURR-001 had gained noticeably more weight and, in a smaller subgroup scanned by ultrasound, thicker back muscles. The two measures tracked together, which is what you would hope to see if real muscle, not just fat, was being added. Routine blood work showed no sign of organ toxicity.

There are important caveats. Only 27 cats finished, the muscle-scan group was just 15 animals, and the study never tested whether the three-drug cocktail beats any single ingredient. A blood gene-expression readout meant to reveal the drug’s mechanism found essentially nothing. One treated cat died of severe pancreatitis, judged unrelated by the vets. Still, as a first controlled demonstration that feline age-related muscle loss is pharmacologically movable, it is a genuine opening rather than a conclusion.

Insights

The honest first message is that this is a cat study, and nothing here has been shown to work in humans. What it offers is a directional signal about a strategy that longevity researchers already find promising.

To see how big the reported effect actually is, effect size is the useful lens. Effect size asks not just whether a difference is real, but how large it is relative to the natural spread between individuals. A common yardstick is Cohen’s d, where roughly 0.2 is small, 0.5 is medium, and 0.8 or above is large. For body mass gain, the gap between drug and placebo works out to a Cohen’s d of about 0.95, a large effect. For back-muscle thickness it is even larger, roughly 1.4 to 1.5, though that came from only 15 cats so the true number is uncertain.

In plain terms, a typical 3.5 kg elderly cat on the drug gained roughly a quarter of a kilogram, versus almost nothing on placebo. The take-home for people is conceptual; combining several modest interventions that each nudge a different aging pathway may beat searching for one blockbuster, and preserving muscle is worth prioritizing as any mammal ages.

Context and Source

Leitura Relacionada:

RapAdmin

gem1
gem12752×1536 386 KB

A large international team reports that gemfibrozil, a cheap fibrate drug prescribed since the 1970s to lower blood fats, extends lifespan in yeast and worms and improves the health of aged mice. The surprise is the mechanism. The longevity effect has nothing to do with PPAR-alpha, the receptor that fibrates are famous for hitting. Instead, gemfibrozil binds and jams a cell-surface transporter called PEPT1 (Slc15a1) that normally ferries small peptides into cells. With the peptide door partly shut, cells absorb fewer amino acids, mTOR signalling drops, and the animals enter a state that looks biochemically like protein restriction or calorie restriction, without actually eating less. The authors frame gemfibrozil as a candidate “dietary restriction mimetic” already sitting on pharmacy shelves.

For decades the most reliable way to make an animal live longer has been to feed it less, or to feed it less protein. The problem is that almost no human sticks to that regimen. So the field keeps hunting for a pill that copies the internal signal of restriction while the person keeps eating normally. Rapamycin does it by blocking mTOR directly. Metformin and acarbose do it, roughly, through glucose handling. This paper nominates an unlikely new member of that club: gemfibrozil, a generic lipid drug most people have never heard of.

The researchers, led out of the National University of Singapore with the Buck Institute and Texas A&M, ran the drug through an unusually complete evolutionary gauntlet. In budding yeast it lengthened replicative lifespan by roughly a quarter. In roundworms it added about a tenth to median lifespan and kept the animals moving and stress-resistant later into life. Then they did the detective work to explain why.

The expected answer, PPAR-alpha, failed every test. Deleting the yeast versions of that target did not abolish the benefit, and two sister fibrate drugs did nothing at all. Using a protein-melting assay, the team caught gemfibrozil physically gripping a different protein entirely: PEPT1, the intestinal peptide transporter. Binding stiffened PEPT1 and choked off its ability to import di-peptides. Starve a cell of imported peptides and you starve it of amino acids, and amino acids are the fuel that switches on mTOR, the master growth engine that restriction is thought to quiet.

The pattern held across kingdoms. Yeast, worms, a human prostate cancer cell line, and slices of mouse intestine all imported fewer peptides and held lower internal amino acid levels after gemfibrozil. Genetically deleting the same transporters extended lifespan on their own, and once they were gone the drug added nothing, the signature of a drug and a gene acting on one shared pathway.

The headline mammalian result is health, not lifespan. Twenty-month-old female mice, already elderly, were put on gemfibrozil-laced chow. Over the following months their frailty scores climbed more slowly than untreated controls, with better grip strength, hearing, and coat-independent markers of vigour, and fewer deaths. This is preliminary and the mouse numbers are small, but the direction is consistent with everything upstream.

Insights

What the paper does reinforce is the underlying lever: lowering the flux of amino acids into your cells, especially from protein, quiets the growth pathway (mTOR) that appears to accelerate aging. The drug is essentially a chemical shortcut for what protein moderation does naturally.

How big is the effect? In the simplest, most translatable measurement, aged mice on the drug accumulated frailty 35 to 45 percent more slowly than untreated mice, and their death rate over the study window fell from 40 percent to about 22 to 27 percent. In relative terms that is roughly a one-third to nearly one-half reduction in the odds of dying during that window. Those are large numbers for a drug repurposing, but they come from small groups of mice and a short window.

Context and Source

  • Open Access Paper: Gemfibrozil promotes longevity and health by restricting amino acid uptake through the Dipeptide transporter, PEPT1.
  • Lead institution and country: National University of Singapore (Healthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine), Singapore, with major contributions from the Buck Institute for Research on Aging (California, USA) and Texas A&M University (USA).
  • Corresponding author: Brian K. Kennedy.
  • Journal: npj Aging (Nature Portfolio / Springer Nature).
  • Impact evaluation: Reported metrics cluster around a Journal Impact Factor of roughly 6.0 (2024 to 2025 figures range from about 5.3 to 6.0 across independent trackers) and a CiteScore of about 6. Note that Nature’s own metrics page currently displays a considerably higher figure that does not agree with the independent aggregators, so the ~6 value is the more defensible one. Using the requested framing: the impact score of this journal is approximately 6.0, evaluated against a typical high-end range of 0 to 60+ for top general science journals, therefore this is a Medium impact journal.

Leitura Relacionada:

gemfibrozil_news_image
gemfibrozil_news_image3840×2160 399 KB

RapAdmin

ConboyResearch3Drug
ConboyResearch3Drug2752×1536 419 KB

Researchers at UC Berkeley combined two inexpensive, widely available metabolic drugs, dichloroacetate and metformin, with a ten-fold reduced dose of the experimental senolytic navitoclax (ABT-263) to create a three-drug cocktail they call DMA. The core idea is that both cancer cells and worn-out senescent cells share the same metabolic weakness: leaky, inefficient mitochondria and an over-reliance on fragile ATP production. DMA pushes these already-strained cells over the edge into an energy collapse, while healthy cells with robust metabolism shrug it off. In cell culture DMA killed multiple cancer lines and several types of senescent cells, including navitoclax-resistant ones, without the platelet toxicity that has stalled navitoclax in the clinic. In old mice, short courses improved treadmill endurance, and prolonged dosing modestly extended lifespan. The work is preliminary, mechanistically interesting, and comes with significant caveats about sample size and translation.

For years the dream of treating aging and cancer with the same drug has run into the same wall: the drugs that kill senescent cells, the so-called senolytics, tend to be toxic. Navitoclax, one of the most promising, drops platelet counts so sharply that it can cause dangerous bleeding, and many cancers simply ignore it. The Berkeley team asked a different question. Instead of hitting these cells harder, could you exploit what makes them fragile in the first place?

Their answer targets metabolism. Cancer cells and senescent cells both run their mitochondria poorly. They leak protons, waste energy, and lean heavily on glycolysis and a thin margin of ATP to stay alive. The team reasoned that if you gently sabotage energy production with two old metabolic drugs, metformin and dichloroacetate, you could make these cells so energetically brittle that even a small, normally safe dose of navitoclax would finish them off. Healthy cells, with efficient mitochondria and spare capacity, would ride it out.

That is roughly what happened in the dish. The combination, DMA, wiped out senescent lung fibroblasts and killed cancer lines from cervical, breast, and colon tumors, including a breast line that resists navitoclax on its own. It did this by draining cellular ATP to near zero in the sick cells while leaving healthy neurons, liver cells, and muscle precursors largely intact. Crucially, the reduced navitoclax dose no longer crashed platelet counts.

The animal data are more modest but intriguing. Old mice given short courses ran longer on a treadmill and showed no loss of strength, balance, or increase in frailty. Their blood showed a drop in inflammatory and senescence-associated proteins, nudging their molecular profile toward that of younger animals. When dosing continued for life, treated mice lived a median of 187 days longer than controls, and their serum proteome drifted younger.

The significance is conceptual as much as practical. Rather than inventing a new toxic drug, the team repurposed cheap, familiar molecules by aiming at a shared metabolic soft spot. If it holds up in larger, better-controlled studies, it points toward affordable, low-toxicity ways to clear the cellular debris that drives both aging and cancer. That “if” is still doing heavy lifting.

Actionable Insights

The take-home message is that this is a mouse and cell study, so there is nothing here to act on directly. What it offers is a direction and a sense of scale.

The headline benefit is lifespan. Mice that started treatment at old age (around 18 months) and continued for life reached a median lifespan of 1002 days versus 815 days for untreated mice. That is 187 extra days, a 22.9 percent longer median lifespan. Averaged across all animals the gain was smaller, roughly 12 to 14 percent. Measured only over the time after treatment began, survival stretched by about 41.7 percent, but that larger-sounding number is inflated by starting the clock late in life.

The functional benefit was endurance. Old treated mice improved their month-over-month treadmill running time significantly more than controls, without losing grip strength or gaining frailty. In cells, the effect sizes were large: senescent cells were cleared by roughly 60 to 90 percent, cancer-cell apoptosis rose about tenfold, and cancer-cell division dropped about sevenfold.

Two of the three ingredients, metformin and dichloroacetate, are already human drugs, which is why this line of work matters. But the third is not benign, the doses and delivery were tuned for mice, and no human has taken this combination. Treat it as a research signal, not a protocol.

Context and Source

  • Open Access Paper: Selective targeting of cancer and senescence via shared metabolic shifts extends lifespan of old mice.
  • Institution and country: Department of Bioengineering and QB3 Institute, University of California, Berkeley, USA. Senior author Irina M. Conboy. Note a declared conflict of interest: the senior author is co-founder and Chief Scientific Officer of Generation Lab, though the paper states the work was conducted independently of the company.
  • Journal: Aging (also known as Aging-US), published by Impact Journals
    Impact evaluation: The most recent Journal Impact Factor is about 3.9 (2023 edition), trending down to roughly 3.2 in the 2024 edition, from a historical peak near 6.4 in 2014. Using the current figure: The impact score of this journal is approximately 3.9, evaluated against a typical high-end range of 0 to 60+ for top general science journals, therefore this is a Low-to-Medium impact journal. Two reputational caveats belong alongside that number: the journal appeared on Beall’s list of potentially predatory open-access journals in 2015, and it has faced criticism over self-citation practices. This does not invalidate the science, but it lowers the prior on stringent peer review.

RapAdmin

XprizeLongevityFinalists
XprizeLongevityFinalists1920×1072 333 KB

Here is the shortlist of the XPRIZE $100 Million Healthspan “Top 10” finalists (from the Milestone 2 Awardee Lookbook, Appendix F, attached below), with each team’s approach and its stated mechanism of action.

AgelessRx (Ann Arbor, MI) — A telehealth-delivered combination “longevity medicine” protocol. It stacks rapamycin, low-dose naltrexone, metformin, NAD+, glutathione, sermorelin, and tirzepatide with resistance training and health coaching. Mechanism: hits several aging pathways at once — mTOR inhibition, AMPK activation, NAD+ repletion, oxidative-stress reduction, and growth-hormone-axis signaling — plus a proprietary “Infinite Supplement” blend (alpha-ketoglutarate, quercetin, glucosamine, carnosine, pterostilbene, astaxanthin, curcumin).

Goda Lab (University of Tokyo / NanoTitan / Tohoku University / Tokyo Relife Clinic, Japan) — Engineered extracellular vesicles (EVs) from stem cells or plasma. Its “super homotypic targeting” (SHT) platform reprograms EV surfaces for precise tissue delivery. Mechanism: strengthens EV affinity for cells of origin to deliver regenerative miRNAs and proteins to muscle, neural, and immune tissue; preclinically suppressed p16 and p21 and reduced inflammation, targeting multiple hallmarks of aging simultaneously.

Johns Hopkins–Suninflam (Baltimore, MD & San Francisco, CA) — SIF001, a second-generation monoclonal antibody against Galectin-3 (Gal-3), aimed at subclinical Alzheimer’s/MCI. Mechanism: a dual immune/inflammation-and-aggregation approach — blocks Gal-3-mediated chronic inflammation, inhibits Gal-3 oligomerization to prevent amyloid-beta aggregation, and disrupts monocyte/macrophage activation and regulatory T-cell suppression, targeting a shared upstream driver of age-related inflammatory dysregulation.

Longeveron Inc. (Miami, FL; Nasdaq: LGVN) — Laromestrocel (Lomecel-B), an allogeneic bone-marrow-derived mesenchymal stem cell (MSC) therapy for aging-related frailty and Alzheimer’s. Mechanism: a pleiotropic MSC effect — pro-vascular, immunomodulatory, and tissue-repair actions, plus paracrine anti-inflammatory signaling, neuroinflammation suppression, and mitochondrial transfer to damaged cells; positioned to counter “inflammaging” across multiple conditions at once.

Minicircle (Austin, TX) — A non-viral plasmid (“minicircle”) gene therapy delivering two gene cassettes, follistatin (FST) and klotho (KL), by subcutaneous injection. Mechanism: follistatin inhibits myostatin/activin signaling to build muscle and reduce inflammation; klotho modulates FGF23 signaling for systemic anti-aging and neuroprotection — delivered via a transfection reagent-complexed episomal plasmid to avoid viral-vector cost and complexity.

NYC-Vita (Mount Sinai, New York, NY) — A randomized trial combining low-dose rapamycin, spermidine, and structured HIIT/resistance exercise in adults 50–90, with deep multi-omics phenotyping. Mechanism: rebalances aging macrophages to cut chronic inflammation while targeting metabolic, muscle, and cognitive decline — rapamycin inhibits mTOR and suppresses the SASP; spermidine restores autophagy and reduces aging-driven myelopoiesis; home-based exercise drives tissue repair.

Mitochondrial All Stars (Mighty Therapeutics + University of Washington Nathan Shock Center; Needham, MA & Seattle, WA) — Repurposing elamipretide (SS-31 peptide), described as the first and only FDA-approved mitochondria-targeting peptide, as a healthspan intervention. Mechanism: binds cardiolipin in the inner mitochondrial membrane to stabilize/improve mitochondrial function, with associated benefits to brain and muscle function and reduced inflammation markers.

RETRO-EPIGERNA (Macau University of Science and Technology, China) — The KYN Composite Capsule, combining medicinal/edible Chinese herbs and probiotics, built on a discovery linking a specific tRNA epitranscriptional modification to aging. Mechanism: restores that tRNA modification to improve translational fidelity and proteostasis, mitochondrial function, and immune resilience — framed as a multi-system route to reversing aging.

RPRGAON / PRG S&Tech — Progerinin (Busan, South Korea) — Progerinin, a small molecule developed originally for Hutchinson-Gilford Progeria (HGPS), now aimed at general aging. Mechanism: inhibits the progerin–lamin A interaction to drive selective progerin degradation, restoring nuclear membrane/lamina architecture and reversing markers of cellular senescence and genomic instability (progerin also accumulates in normally aging arteries, muscle, and fat).

TIME TRAVELER — Plant-EVs (TIME TRAVELER Corp., Tokyo, Japan) — Parsley-derived plant extracellular vesicles (P-EVs), taken as a dietary supplement ("exofull FUJI"), screened from 140+ edible plant species. *Mechanism:*selected for anti-inflammatory and anti-senescence properties; a proprietary non-thermal, low-stress extraction (“FROZEN-TT01”) preserves purity and biological activity, intended to mitigate age-related declines in muscle strength and physical function.

A quick pattern across the ten: three broad mechanistic camps dominate — combination pharmacologic/lifestyle protocols targeting mTOR/AMPK/NAD+ (AgelessRx, NYC-Vita), cell- and vesicle-based regenerative therapies (Goda Lab, Longeveron, TIME TRAVELER), and targeted molecular interventions against a specific aging driver (Johns Hopkins–Suninflam’s Gal-3, Progerinin’s progerin, Minicircle’s follistatin/klotho, Mitochondrial All Stars’ cardiolipin, RETRO-EPIGERNA’s tRNA modification).

Full report for free download:

Leitura Relacionada:

RapAdmin

BMJ-HeartHealth
BMJ-HeartHealth2752×1536 493 KB

A large UK Biobank study tracked more than 17,000 middle-aged and older adults who wore wrist accelerometers and had their fitness estimated on an exercise bike. Over roughly eight years it mapped how the combination of measured exercise and cardiorespiratory fitness relates to heart disease. The headline result is sobering for anyone who treats the familiar 150 minutes per week target as a finish line. Meeting that guideline was linked to only about an 8 to 9 percent lower risk of cardiovascular disease. Cutting risk by 30 percent appeared to require roughly 560 to 610 minutes per week, three to four times the minimum. Fitness itself carried an independent protective signal, and a genetic analysis pointed toward higher fitness lowering heart failure risk in particular.

For two decades the public health message on exercise has been reassuringly simple: get 150 minutes of moderate-to-vigorous activity a week and your heart will thank you. A new analysis in the British Journal of Sports Medicine suggests that message is true but oversells how much the minimum actually delivers.

Researchers led by a team at Macao Polytechnic University used the UK Biobank, drawing on 17,088 participants who wore research-grade wrist accelerometers for a week and who also completed a submaximal cycling test to estimate their maximal oxygen uptake, the gold-standard index of cardiorespiratory fitness. Rather than looking at exercise or fitness in isolation, as most previous work has done, they modelled the two together as a joint dose-response surface and watched who developed atrial fibrillation, heart attack, heart failure or stroke over a median of 7.85 years.

The big idea is that the standard guideline is a floor, not a target. Hitting 150 minutes a week was associated with a hazard ratio of about 0.91 to 0.92, an 8 to 9 percent reduction in cardiovascular risk, and that modest benefit held remarkably steady whether a person was unfit or highly fit. To reach the kind of protection that people often assume the guideline provides, a 20 percent reduction, participants needed roughly 340 to 370 minutes a week. For a 30 percent reduction the figure climbed to roughly 560 to 610 minutes, close to an hour and a half a day.

There is an important nuance behind the modest headline number. Earlier studies that reported 20 to 30 percent risk reductions at the guideline dose mostly relied on self-reported activity and did not separately account for fitness. Because this study statistically strips out fitness, its 8 to 9 percent figure captures the effect of the behaviour alone, isolated from the physiological reserve that regular activity slowly builds. In other words the guideline probably does more than 8 percent in the real world, because sustained activity also raises fitness over time, and fitness carries its own protection.

The authors also ran a Mendelian randomisation analysis, using genetic variants as natural randomisers to probe causality. Genetically higher fitness was tied to lower heart failure risk, while genetic signals for activity itself were weaker and less consistent, a familiar pattern given how hard habitual behaviour is to capture with genes. The practical takeaway is a fitness-calibrated prescription: the minimum keeps you safe, but real cardiovascular gains demand substantially more.

Actionable Insights

The single most useful lesson here is a recalibration of expectations. Think of the 150 minutes a week guideline as clearing a low bar rather than winning the race. In this study, hitting that target was linked to only about an 8 to 9 percent lower chance of a serious heart problem. To gauge how big that is, researchers use a standard yardstick that rates effects as negligible, small, medium or large. This one lands at negligible. That does not make the minimum pointless. It is a floor that keeps you out of the highest-risk zone, not a target that delivers big protection.

If you want a real reduction, the pattern is simple: more is more. Cutting risk by 20 percent lined up with roughly 340 to 370 minutes a week. Cutting it by 30 percent took roughly 560 to 610 minutes, which works out to about 80 to 90 minutes a day. The payoff keeps growing as you do more, but even at the high end the effect stays in the small range on that same yardstick. Small is still worth having, especially when it is spread across millions of people, but no single dose here is a magic bullet.

Fitness counts on its own, separately from how much you move. People with higher measured fitness had lower risk regardless of their exercise minutes, on the order of about 10 percent lower risk for a meaningful step up in fitness. And starting out less fit costs you: those individuals needed roughly 30 to 50 more minutes a week than fitter people to earn the same relative benefit. The practical message is to treat 150 minutes as your entry point, push toward much higher weekly totals if you can, and aim to actually raise your fitness over time, not just log the minutes.

Context and Source

Leitura Relacionada:

RapAdmin

BloodpressureBrain
BloodpressureBrain2752×1536 342 KB

Tracking more than 12,000 American adults for over two decades, researchers translated familiar midlife risk factors, diabetes, high blood pressure, and smoking, into a single number people can actually feel: years of life spent alive and free of dementia. Adults who entered their mid-fifties with none of the three risk factors averaged about 30 dementia-free years between ages 55 and 95, while those carrying all three averaged only about 17.5, a gap of roughly 12 to 13 years. A paradox sits inside the finding. The high-risk group showed lower lifetime dementia rates, not because their brains were protected, but because they died earlier of cardiovascular and other causes before dementia could be diagnosed. The take-home is that vascular health in midlife buys both a longer life and more of that life with your cognition intact.

For decades, prevention messaging has asked people to lower abstract probabilities. Cut your risk of dementia by some percentage. Reduce your relative hazard. These numbers are hard to feel and easy to ignore. A new analysis from the long-running Atherosclerosis Risk in Communities study reframes the same biology in a currency anyone understands: time. Specifically, the number of years a person can expect to live between ages 55 and 95 while remaining free of dementia.

The research team followed 12,409 adults who were alive and dementia-free at age 55, measuring three modifiable risk factors in midlife: diabetes, hypertension, and current smoking. Over a median follow-up of 26 years, 3,008 people developed dementia and 5,238 died without ever developing it. When the team counted up dementia-free years, the gradient was steep and orderly. Zero risk factors bought about 30.1 dementia-free years. One risk factor, 26.3 years. Two, 21.0 years. All three, just 17.5 years. Optimal midlife vascular health was associated with up to 12.6 additional years of cognitively intact life.

The study’s most counterintuitive result is a lesson in why single statistics mislead. People with three risk factors actually had a lower lifetime chance of being diagnosed with dementia by age 95, roughly 23 percent, versus 42 percent for the healthiest group. This is not protection. It is competing mortality. The high-risk group was dying of heart attacks, strokes, and other vascular causes at more than four times the rate before dementia had a chance to develop and be diagnosed. Dementia is, in part, a disease of survivors. Keep people alive and their brains become the organ that eventually fails.

The gradient held across sex, race, and genetic risk, though the absolute numbers differed. Women averaged more dementia-free years than men. Black participants averaged fewer dementia-free years than White participants, a disparity that widened at the highest risk levels and tracks with a heavier vascular burden in that group. Carriers of the APOE-e4 gene, the strongest common genetic risk factor for Alzheimer disease, lost dementia-free years relative to non-carriers, but vascular burden still mattered on top of genetics.

The big idea is a communication tool as much as a scientific one. Telling a 55-year-old that quitting smoking and controlling blood pressure could return years of clear-headed life is more motivating than quoting a hazard ratio. The authors are careful. This is association, not proof of causation, and it rests on a single snapshot of midlife risk. But the direction, the dose-response, and the decades of follow-up all point the same way.

Actionable Insights

The practical message is simple: the vascular risk factors your doctor already nags you about, high blood pressure, diabetes, and smoking, are also brain-longevity levers, and the payoff is measured in years of clear thinking, not just abstract risk reduction.

Here is the magnitude in plain terms. Going from all three risk factors to none was associated with about 12.6 more dementia-free years across the 55-to-95 window. That is a 72 percent increase in dementia-free time relative to the high-risk group, or put the other way, carrying all three risk factors was linked to losing about 42 percent of the dementia-free years the healthiest people enjoyed. Even removing risk factors one at a time mattered on a sliding scale. Zero to one cost about 3.8 years, one to two about 5.3 years, two to three about 3.5 years.

An important caveat on how to read this. Because the study measured risk factors only once in midlife and cannot prove cause, these are best understood as the size of the association, not a guaranteed personal return on quitting smoking tomorrow. The true benefit of actively fixing a risk factor could be smaller. Still, the consistency across every subgroup and the clean dose-response make the direction believable. If you want one number to carry away: optimal midlife vascular health tracked with roughly a decade or more of extra life lived with your mind intact.

Context and Source

  • Open Access Paper: Midlife Vascular Risk Burden and Dementia-Free Survival Years: The Atherosclerosis Risk in Communities Neurocognitive Study.
  • Authors: Jiaqi Hu and colleagues, with Michael Fang and Jordan Weiss as co-senior authors.
  • Lead institutions: Tsinghua University (Beijing, China); NYU Grossman School of Medicine (New York); Johns Hopkins Bloomberg School of Public Health (Baltimore); with collaborators at University of North Carolina, University of Minnesota, University of Mississippi, and the NIH/NINDS. Country: primarily United States (data), with international co-authorship (China and USA).
  • Journal: Neurology: Open Access (published by Wolters Kluwer on behalf of the American Academy of Neurology).
  • Impact evaluation: Neurology: NA. Journal launched in March 2025, so as of this analysis it has no established Journal Impact Factor or CiteScore.

RapAdmin

Overview
Overview1920×1072 309 KB

This review argues that aging has shifted from an inevitable decline to a modifiable, systems-level process, and that healthspan rather than raw lifespan is now the practical target. It stratifies the entire anti-aging toolkit into what is clinically validated today (lifestyle interventions and a handful of repurposed drugs) versus what remains preclinical and speculative (senolytic vaccines, CAR-T against senescent cells, partial epigenetic reprogramming, young plasma factors). The core message is that no single lever moves aging much on its own, so the credible path forward is multimodal, biomarker-guided, combination strategies, monitored with molecular aging clocks and AI-enabled wearables, and validated through better-designed trials with composite endpoints.

For most of medical history, aging was treated as the weather: something you endure, not something you change. This review documents how thoroughly that assumption has collapsed. Aging is now framed as a set of interacting biological programs, the “hallmarks,” and each hallmark is a potential drug target. The authors survey the whole battlefield and refuse to pretend the war is won.

The big idea is stratification by evidence. At the base sit lifestyle interventions, which the authors repeatedly call the most mature and cost-effective tools available. Caloric restriction, various fasting protocols, Mediterranean and DASH dietary patterns, structured exercise, protected sleep, and active social lives each nudge multiple aging pathways at once. Their advantage is not that any one of them is dramatic, but that they are safe, accessible, and additive. When combined, the review argues, they interact biologically and deliver larger system-wide gains than any isolated fix.

One tier up sit repurposed pharmaceuticals with human data: rapamycin for the mTOR pathway, metformin and the newer GLP-1 and SGLT2 drugs for metabolic aging, NAD precursors, spermidine and urolithin A for autophagy and mitochondrial cleanup, and low-dose colchicine for chronic inflammation. These show cross-tissue benefits in animals and encouraging but incomplete human signals.

Then the review climbs into more speculative territory: drugs and vaccines that selectively kill senescent “zombie” cells, engineered immune cells that hunt those cells down, transplanted microbiomes, and circulating “youth factors” from young blood. Highest and least proven of all is partial epigenetic reprogramming, the idea of resetting a cell’s age using a subset of the Yamanaka factors without erasing its identity. In mice this has restored vision and, in one striking result, more than doubled the remaining lifespan of very old animals. In humans it has never been tested.

Running through all of this is a monitoring layer: DNA methylation aging clocks, retinal and facial aging estimators, and wearables that passively track heart rate variability, sleep, and even speech. The authors are careful to note these clocks are not yet accepted by regulators as proof that a therapy works. The honest conclusion is that the field has a rich menu and a weak evidence base, and that the fix is better trials, not louder claims.

Actionable Insights

The genuinely take-home, do-it-today material lives almost entirely in the lifestyle and repurposed-drug tiers. Extracted effect sizes, so the magnitude is not hidden behind adjectives:

Caloric restriction (CALERIE trial, 218 adults, 25 percent restriction, 2 years): slowed the pace of biological aging on the DunedinPACE clock by 2 to 3 percent, which the authors translate to a 10 to 15 percent reduction in mortality risk. That is a real but modest signal, and it is a surrogate-clock estimate, not counted deaths.

Intermittent fasting (meta-analysis, over 1,200 participants): roughly 15 to 20 percent lower insulin resistance (HOMA-IR) and 3 to 5 mmHg lower systolic blood pressure, comparable to caloric restriction but with better adherence.

Mediterranean diet: associated with an 11 to 30 percent lower risk of age-related cognitive disorders and about 30 percent lower cardiovascular event incidence in high-risk people. These are observational associations, so residual confounding likely inflates them.

Exercise: resistance training raised maximal strength by about 30 percent over 12 weeks; aerobic training improved flow-mediated dilation by 3 to 5 percent. Progressive resistance work is the most reliable single intervention for preserving strength and bone.

Low-dose colchicine (0.5 mg/day): the review reports a 22 percent reduction in age-related cardiovascular comorbidities and an 18 percent reduction in all-cause mortality. Treat the mortality figure with caution (see limitations).

Social connection: social isolation carried a pooled hazard ratio of 1.32 for all-cause mortality (95 percent CI 1.26 to 1.39), meaning isolation raised death risk by about a third. Staying socially engaged is a free, high-leverage intervention.

Bottom line for a practitioner: the evidence-backed protocol is unglamorous. Move calories down modestly or compress the eating window, train for strength and aerobic capacity, protect 7 to 9 hours of sleep, eat a plant-forward Mediterranean-style diet, stay socially and cognitively active. Consider the repurposed drugs for further longevity and healthspan benefits.

Context / Source

  • Open access paper: Advances in anti-aging strategies
  • Type: Review article.
  • Institution: Xiangya Hospital, Central South University, Changsha, Hunan, China (with affiliated national geriatric and aging-medicine laboratories).
  • Country: China.
  • Journal: Cell Aging and Regeneration, published by AccScience Publishing (Singapore). DOI: 10.36922/CAR025440003. Published online July 20, 2026.
  • Impact evaluation: Cell Aging and Regeneration is a newly established journal. It has no Journal Impact Factor and no CiteScore, because both metrics require a multi-year citation history after indexing in Web of Science (for JIF) or Scopus (for CiteScore), and the journal has not existed long enough to accrue one.